-
摘要: 恶性肿瘤发病率近年来逐渐上升,成为引起死亡的首要原因之一。发展特异性强,敏感度高的影像诊断手段,对肿瘤的早期发现、早期治疗具有重要意义。动态增强磁共振成像(DCE-MRI)是通过静脉注射小分子顺磁性对比剂无创地评价组织血流灌注、渗透性等血管特性的功能性成像方法,目前主要应用于诊断及鉴别诊断全身多系统良恶性病变、动态监测肿瘤放化疗治疗效果、评估肿瘤抗血管生成治疗的疗效等方面。在本研究中作者主要对钆对比剂在DCE-MRI中的应用和前景作一综述。
-
[1] Boss MK, Muradyan N, Thrall DE. DCE-MRI: a review and applications in veterinary oncology[J]. Vet Comp Oncol, 2013, 11(2): 87-100. [2] Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker[J]. J Clin Oncol, 2006, 24(20): 3293-8. [3] Hillman GG, Singh-Gupta V, Al-Bashir AK, et al. Dynamic contrast- enhanced magnetic resonance imaging of sunitinib-induced vascular changes to schedule chemotherapy in renal cell carcinoma xenograft tumors[J]. Transl Oncol, 2010, 3(5): 293-306. [4] Agner SC, Rosen MA, Englander SA, et al. Computerized image analysis for identifying triple-negative breast cancers and differentiating them from other molecular subtypes of breast cancer on dynamic contrast-enhanced Mr images: a feasibility study[J]. Radiology, 2014, 272(1): 91-9. [5] Türkbey B, Thomasson D, Pang Y, et al. The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment[J]. Diagn Interv Radiol, 2010, 16(3): 186-92. [6] Nci C. 5-Tesla and endpoints for use in phase 1/2a trials of anticancer therapeutics affecting tumor vascular function,MR workshop on translational research in cancer:recommendations for MR measurement methods at 1[R], 2008: 1-10. [7] Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA Mr imaging [J]. J Magn Reson Imaging, 1997, 7(1): 91-101. [8] Murase K. Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging[J]. Magn Reson Med, 2004, 51(4): 858-62. [9] Sourbron SP, Buckley DL. Classic models for dynamic contrast-enhanced MRI[J]. NMR Biomed, 2013, 26(8, SI): 1004-27. [10] Choyke PL, Dwyer AJ, Knopp MV. Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging[J]. J Magn Reson Imaging, 2003, 17(5): 509-20. [11] Tuncbilek N, Tokatli F, Altaner S, et al. Prognostic value DCE-MRI parameters in predicting factor disease free survival and overall survival for breast cancer patients[J]. Eur J Radiol, 2012, 81(5): 863-7. [12] El Khouli RH, Macura KJ, Jacobs MA, et al. Dynamic contrast-enhanced MRI of the breast: quantitative method for kinetic curve type assessment[J]. AJR Am J Roentgenol, 2009, 193 (4):W295-300. [13] Schnell CR, Stauffer F, Allegrini PR, et al. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging[J]. Cancer Res, 2008, 68(16): 6598-607. [14] ]Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer[J]. J Clin Oncol, 2006, 24(5): 769-77. [15] Padhani AR, Khan AA. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy[J]. Target Oncol, 2010, 5(1): 39-52. [16] Edelman RR, M AM, Atkinson DJ, et al. C erebral blood flow: assessment with dynamic contrast-enhanced T2*WI Mr imaging at 1.5T[J]. Radiology, 1990, 176(1): 211-20. [17] Simonsen CZ, Ostergaard L, Smith DF, et al. Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking[J]. J Magn Reson Imaging, 2000, 12(3): 411-6. [18] Ichikawa T, SaitoK,YoshiokaN, et al. Detection and characterization of focal liver lesions a Japanese phase III, multicenter comparison between gadoxetic acid disodium-Enhanced magnetic resonance imaging and Contrast-enhanced computed tomography predominantly in patients with hepatocellular[J]. Invest Radiol, 2010, 45(3): 133-41. [19] Kuhl CK. MRI of breast tumors[J]. Eur Radiol, 2000, 10(1): 46-58. [20] Kvistad KA, Rydland J, Vainio J, et al. Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted Mr imaging and with T2*-weighted first-pass perfusion Mr imaging[J]. Radiology, 2000, 216(2): 545-53. [21] Knopp MV, Junkermann H, Sinn HP. Monstrous breast tumor[J]. Radiologe, 1995, 35(5): 363-6. [22] Reiners KS, Gossmann A, Von Strandmann EP, et al. Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma[J]. J Immunother, 2009, 32(5): 508-12. [23] Ibrahim MA, Haughton VM, Hyde JS. Enhancement of intervertebral disks with Gadolinium complexes: comparison of an Ionic and a nonionic medium in an animal model[J]. AJNR Am J Neuroradiol, 1994, 15(10): 1907-10. [24] Ibrahim MA, Jesmanowicz A, Hyde JS, et al. Contrast enhancement of normal intervertebral disks: time and dose dependence[J]. AJNR Am J Neuroradiol, 1994, 15(3): 419-23. [25] Engelbrecht MR, Huisman HJ, Laheij RJ, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced Mr imaging [J]. Radiology, 2003, 229(1): 248-54. [26] Turnbull LW. Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer[J]. NMR Biomed, 2009, 22(1): 28-39. [27] Verma S, Turkbey B, Muradyan N, et al. Overview of dynamic Contrast-Enhanced MRI in prostate cancer diagnosis and management [J]. AJR Am J Roentgenol, 2012, 198(6): 1277-88.
点击查看大图
计量
- 文章访问数: 552
- HTML全文浏览量: 211
- PDF下载量: 9
- 被引次数: 0